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NAD plays an essential role in a number of biological processes. A study in this issue of Cell Metab-
olism (Revollo et al., 2007b) demonstrates that nicotinamide phosphoribosyltransferase (Nampt),
also known as PBEF or visfatin, is a secreted enzyme and a source of systemic NAD. The authors
show that Nampt-mediated NAD synthesis is necessary for b cell function, providing fresh insights
into the pathophysiology of metabolic diseases.Nicotinamide adenine dinucleotide
(NAD) is an electron carrier that en-
ables our body to produce ATP. By
accepting a hydride ion (H) from a
substrate molecule, NAD is trans-
formed to a reduced form (NADH)
through glycolysis and the TCA cycle
and then serves as an electron donor
in vital processes, such as acetyl-
CoA synthesis from pyruvate and the
generation of ATP in oxidative phos-
phorylation. Recently, this ‘‘classic’’
view of NAD has been refreshed by
the discovery that yeast silent infor-
mation regulator 2 (Sir2) and its mouse
ortholog sirtuin 1 (SIRT1) are NAD-
dependent deacetylases (Imai et al.,
2000). Based on the finding that Sir2
and its orthologs extend life span in
yeast, C. elegans, and Drosophila
(Guarente, 2006), it is conceivable to
postulate that NAD availability may
be the missing link between aging
and energy homeostasis.
In the current issue, Revollo, Ko¨rner,
and colleagues (Revollo et al., 2007b)
demonstrate that Nampt (also known
as PBEF or visfatin) is an extra- as
well as intracellular NAD biosynthetic
enzyme that converts nicotinamide
(a form of vitamin B3) to nicotinamide
mononucleotide (NMN), a NAD precur-
sor. Strikingly, the authors find that
NMN synthesis by Nampt is essential
for the maintenance of NAD levels
in pancreatic islets and for normal
glucose-stimulated insulin secretion
(GSIS) from b cells (Revollo et al.,
2007b), leading them to a novel hy-pothesis that NMN functions as a sys-
temic signaling molecule that modu-
lates b cell function. Indeed, Nampt-
deficient heterozygous (Nampt+/)
females showed decreased levels of
plasma NMN and islet NAD and ex-
hibited defective insulin secretion and
impaired glucose tolerance (Revollo
et al., 2007b). Furthermore, defects in
NAD content, GSIS, and glucose toler-
ance in Nampt+/ mice were all ame-
liorated by NMN supplementation
(Revollo et al., 2007b). These findings
suggest that the systemic NAD pool
is maintained at least in part by Nampt
and that NAD supply is a critical deter-
minant of insulin secretion (Figure 1).
Nampt/PBEF/visfatin was first iden-
tified as pre-B cell colony-enhancing
factor (PBEF), a presumptive cyto-
kine-like protein (Samal et al., 1994).
The molecule drew much attention
when Fukuhara et al. (2005) reported
it as a visceral fat-derived adipocyto-
kine and renamed it as visfatin. In
Fukuhara et al. (2005) study, visfatin
was shown to be upregulated during
adipocyte differentiation and detected
in cell culture media and plasma. The
most surprising findings were that vis-
fatin binds directly to the insulin recep-
tor, activates downstream signaling
cascades, and thereby mimics insulin
action in vitro and in vivo (Fukuhara
et al., 2005). Since heterozygous dele-
tion of the visfatin gene (visfatin+/) re-
sulted in a modest rise in plasma glu-
cose levels, the authors concluded
that this defect is due to the lack of insu-Cell Metabolism 6,lin-mimetic effects of visfatin. However,
because plasma visfatin levels were re-
ported to be less than one-tenth of insu-
lin levels despite similar affinity for the
insulin receptor (Fukuhara et al., 2005),
the physiological relevance of visfatin
function has been a subject of debate.
Previously, Martin et al. (2001) re-
ported that the protein product of the
nadV gene has considerable sequence
homology to PBEF. nadV is a plasmid-
encoded gene in Haemophilus ducreyi
that is essential for the bacteria to
grow in NAD-free media (Martin et al.,
2001). Highly conserved amino acid
sequences among NadV/PBEF homo-
logs in human, mouse, carp, sponge,
and bacteria; the ability to synthesize
NMN as a protein and when expressed
in mammalian cells; and the crystal
structure of the PBEF-NMN complex
(Revollo et al., 2007a) all strongly sup-
port the idea that PBEF/visfatin is the
mammalian Nampt, the rate-limiting
enzyme in NAD synthesis first de-
scribed more than 40 years ago (Die-
trich et al., 1966). However, Fukuhara
et al. (2005) do not seem to have con-
sidered visfatin’s homology to NadV
or NadV’s function when interpreting
the phenotype of visfatin+/ mice, leav-
ing room for further debate as to the
true physiological role of this molecule.
What, then, is the physiological
function of this protein? Is it actively
secreted? Does it work as a hormone,
an enzyme, or both? Revollo et al.
(2007b) and another recent report
(Tanaka et al., 2007) clearly show thatNovember 2007 ª2007 Elsevier Inc. 341
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PreviewsFigure 1. Control of Insulin Secretion by Nampt/PBEF/Visfatin
Nampt/PBEF/visfatin secreted from adipose tissue converts nicotinamide to NMN, possibly in the plasma. NMN, which crosses the plasma mem-
brane by an unidentified mechanism, is converted intracellularly to NAD by Nmnat. The b cell NAD pool, supplied by the Nampt/PBEF/visfatin system,
plays an essential role in glucose-stimulated insulin secretion. The NAD-dependent deacetylase SIRT1 may be a candidate molecule linking NAD level
and insulin secretion. Insulin released from the b cells acts on muscle, liver, and adipose tissue in turn. Nampt, nicotinamide phosphoribosyltransfer-
ase; PBEF, pre-B cell colony-enhancing factor; NMN, nicotinamide mononucleotide; NAD, nicotinamide adenine dinucleotide; Nmnat, nicotinamide/
nicotinic acid mononucleotide adenylyltransferase; SIRT1, sirtuin 1.Nampt/PBEF/visfatin is actively se-
creted through a nonclassical path-
way. In their current study, however,
Revollo et al. (2007b) report that they
were unable to reproduce the insulin-
mimetic activity of this protein in terms
of the activation of insulin receptor
signaling, its effects on adipocyte dif-
ferentiation, stimulation of glucose
uptake, and glucose-lowering effect
in vivo. On the other hand, they clearly
demonstrate that mild glucose intoler-
ance in Nampt+/ mice is primarily due
to defective GSIS and that this defect
is rescued by NMN supplementation
(Revollo et al., 2007b). Indeed, glucose
intolerance was similarly observed in
visfatin+/ mice (Fukuhara et al., 2005).
However, the data in Revollo et al.
(2007b) suggest that Nampt/PBEF/
visfatin prevents the upsurge of plasma
glucose by providing NAD and en-
hancing GSIS, not through its insulin-
mimetic effects. Despite other prece-
dent cases of secreted enzymes such
as lipoprotein lipase, which converts
triglycerides to glycerol and fatty acids
in the vessel lumen, it still remains to
be examined whether Nampt is enzy-
matically active in the bloodstream and
whether the other biological effects
(e.g., cytokine-like activity) of this mol-
ecule are attributable to NAD biosyn-
thetic activity.
Insulin secretion is critically regu-
lated by energy availability since inad-
equate insulin levels in plasma cause
detrimental, sometimes fatal, effects.
In b cells, glucose is metabolized to
produce ATP, which in turn closes
ATP-dependent potassium channels
(KATP channels) and activates voltage-
dependent calcium channels, thereby342 Cell Metabolism 6, November 2007 ªpromoting the fusion of insulin-
containing secretory vesicles to the
plasma membrane. The study by Re-
vollo et al. (2007b) provides evidence
that plasma NMN, a key compound
in NAD synthesis, is a novel factor
modulating insulin secretion. The mo-
lecular mechanism by which systemic
NAD biosynthesis regulates b cell
function still remains to be elucidated.
Does NAD pool, instead of NADH/
NAD+ ratio, have significant effects
on KATP channels or other downstream
components? Does it modify KATP-in-
dependent pathways? Or does it work
through the activation of SIRT1, as
suggested by the same authors’ previ-
ous work (Moynihan et al., 2005)? The
biological purpose of such a systemic
NAD biosynthesis mechanism is still
another mystery. In fact, a hypothetical
communication between adipose tis-
sue and pancreatic islets (the adipoin-
sular axis) has long been advocated.
Pajvani et al. (2005) have demon-
strated defective GSIS in mice with an
acute depletion of adipocytes, sup-
porting the idea of adipose tissue-de-
pendent control of insulin release. Ad-
ipose tissue-derived leptin or free fatty
acids may be candidates for such a
mechanism but may not be able to ex-
plain the entire picture. A potential role
of plasma NMN as a novel metabolite
signaling peripheral energy availability
to b cells must await further studies.
Alternatively, Nampt-dependent sys-
temic NAD biosynthesis may be consti-
tutive in nature and may be merely
a prerequisite for the normal function
of b cells. In the latter case, reduced
plasma Nampt or NMN levels may ex-
plain certain pathological conditions,2007 Elsevier Inc.such as type 2 diabetes and age-asso-
ciated decline in b cell function.
Nampt is increased specifically in
mitochondria by hypoxia, serum dep-
rivation, or fasting and prevents cell
death by maintaining the mitochon-
drial NAD pool (Yang et al., 2007),
highlighting the importance of Nampt
as an intracellular source of NAD. The
discovery of a role for Nampt in the
control of systemic NAD biosynthesis
and insulin secretion (Revollo et al.,
2007b) opens a new stage in NAD bi-
ology, ranging from cell stress and nu-
trient sensing to the pathophysiology
of metabolic diseases and aging.
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The NAD-dependent deacetylase
shown to extend life span in seve
onstrate that SIRT1 deacetylates
dependent proteasomal degrada
Sirtuins are NAD-dependent deacety-
lases that target histones, transcrip-
tion factors, and coregulators to adapt
gene expression to the cellular ener-
getic state (Yamamoto et al., 2007).
The founding member of the family,
SIRT1, promotes longevity in species
ranging from yeast to mammals, and
it is believed that these protective ac-
tions may result at least in part from
the beneficial regulation of energy and
metabolic homeostasis. Despite the
impact of high cholesterol levels on
mortality, cholesterol has not been
associated with the sirtuin gene family
until recently. The concentration of
cholesterol, a lipid that maintains cell
membrane structure and is a pre-
cursor for the synthesis of bile acids,
steroids, and vitamin D, is finely tuned.
When the cholesterol concentration
rises in the body, macrophages accu-
mulate cholesterol, favoring the de-
velopment of atherosclerosis, which
negatively affects life span. Excess
cholesterol can be removed from mac-
rophages by high-density lipoprotein
(HDL)-mediated reverse cholesterol
transport (RCT), which redirects cho-
lesterol to the liver for subsequent
elimination via the bile. RCT is con-
trolled by cholesterol transporters and
metabolizing enzymes, which are tran-
scriptionally regulated by the liver XTanaka, M., Nozaki, M., Fukuhara, A.,
Segawa, K., Aoki, N., Matsuda, M.,
Komuro, R., and Shimomura, I. (2007).
Biochem. Biophys. Res. Commun. 359,
194–201.R and Cholestero
1,2,*
ulaire et Cellulaire, CNRS/INSERM/Universi
, France
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SIRT1 regulates lipid and carbohy
ral species. In a recent issue ofMo
and activates the nuclear recep
tion, thereby potentially regulating
receptors (LXRs) a and b, two nu-
clear receptors (NRs) that act as cho-
lesterol sensors (Zelcer and Tontonoz,
2006).
Li et al. (2007) now report that SIRT1
deacetylates and induces LXRa and
b activity. LXR is acetylated on lysine
432 (K432), located within helix 12 of
the ligand-binding domain, whose re-
positioning upon ligandbinding confers
transcriptional activation. Interestingly,
LXR agonists trigger deacetylation
of the receptor, a process in which
SIRT1 plays an important role, since it
interacts with LXR and its absence
blunts LXR deacetylation. However, it
isnot clear at present whetherSIRT1 in-
teracts with LXR in a ligand-dependent
manner or whether the ligand-depen-
dent deacetylation results from confor-
mational changes of the receptor. In
addition, further studies will be required
to identify the acetyltransferases that
promote LXR acetylation.
NRs associate with target pro-
moters and induce transcriptional
activation in a cyclical manner, which
requires rounds of NR ubiquitination
and proteasomal degradation (Reid
et al., 2003). Li et al. (2007) demon-
strate that LXR is hypo-ubiquitinated
and therefore stabilized in the absence
of SIRT1 and that mutation of K432
recapitulates this state, suggesting
Cell Metabolism 6,Yang, H., Yang, T., Baur, J.A., Perez, E.,
Matsui, T., Carmona, J.J., Lamming,
D.W., Souza-Pinto, N.C., Bohr, V.A., Rose-
nzweig, A., et al. (2007). Cell 130, 1095–
1107.l Metabolism
te´ Louis Pasteur, 67404 Illkirch, France
drate metabolism and has been
lecular Cell, Li et al. (2007) dem-
tor LXR by favoring its ligand-
reverse cholesterol transport.
that acetylation of K432 prevents LXR
ubiquitination and its subsequent deg-
radation by the proteasome. Paradox-
ically, but as observed for other NRs,
LXR stabilization by inhibition of its
ubiquitination and proteasomal degra-
dation reduces its transcriptional ac-
tivity, explaining the lower LXR activity
observed in the absence of SIRT1 or
upon mutation of its target site K432.
Interestingly, it seems that it is the
availability of this key lysine residue
more than the acetyl moiety itself that
inhibits ubiquitination and limits LXR
action. Indeed, the mutation of K432
to either arginine or glutamine, which
mimic a constitutively deacetylated
and acetylated lysine, respectively, but
neither of which can be ubiquitinated,
inhibits LXR activity.
The regulation of LXR activity by
acetylation adds this NR to the grow-
ing list of transcriptional regulators
whose activity is regulated by acetyla-
tion. Acetylation has been reported
to regulate the activity of NRs such
as the glucocorticoid and androgen
receptors and steroidogenic factor 1
(SF-1/Ad4BP).SIRT1 also deacetylates
other transcription factors and coregu-
lators (Figure 1; Yamamotoet al., 2007),
and acetylation of transcription factors
synergizes or competes with other
posttranslational modifications such
November 2007 ª2007 Elsevier Inc. 343
